美国生物技术公司Vor Bio周四表示，其实验性肾脏疾病药物在后期研究中减缓了肾功能丧失，并降低了疾病进展的风险。
US biotech company Vor Bio said on Thursday its experimental kidney disease drug slowed the loss of kidney function and reduced the risk of disease progression in a late-stage study.
该研究纳入了患有IgA肾病的患者，这是一种最终可能导致肾衰竭的疾病。
The study included patients with IgA nephropathy, a disease that can eventually lead to kidney failure.
药物特利塔塞普达到了研究的主要目标，并在两年内基本保留了肾功能，而安慰剂组患者出现了更陡峭的下降。Vor Bio表示，该治疗将肾功能确认下降30%的风险降低了89%，将肾功能确认下降40%的风险降低了81%，与安慰剂相比。接受特利塔塞普治疗的患者中，没有人达到预设的肾衰竭终点，而安慰剂组有五名患者达到，其中两人需要透析，公司表示。
Drug telitacicept met the study's main goal and largely preserved kidney function over two years, while patients on placebo saw a steeper decline Vor Bio said the treatment reduced the risk of a confirmed 30% decline in kidney function by 89% and the risk of a confirmed 40% decline by 81% compared with placebo No patient receiving telitacicept reached a predefined kidney failure endpoint, compared with five patients in the placebo group, including two who required dialysis, the company said Protein levels in urine fell 60.3% from baseline after 104 weeks while rising 0.9% in the placebo group, Vor Bio said The company added that the reduction in protein levels was maintained after patients switched from weekly dosing to every-other-week dosing Telitacicept received conditional approval in China in June for adults with IgA nephropathy at risk of disease progression.
Vor Bio表示，尿蛋白水平在104周后从基线下降了60.3%，而安慰剂组上升了0.9%。公司补充称，患者从每周给药改为每两周给药后，蛋白水平的降低得以维持。特利塔塞普今年6月在中国获得有条件批准，用于治疗有疾病进展风险的成人IgA肾病患者。Vor Bio拥有在大中华地区以外开发和销售该药物的权利。
Vor Bio holds rights to develop and market the drug outside Greater China